UroGen Pharma (URGN) Insider George Buys 10,000 Shares
Wildman Daniel George recently acquired 8,000 shares of URGN, adding to insider buying momentum.
Reviewed by automated data checks against the source filing. How we make and check alerts
Wildman Daniel George bought 10,000 shares of UroGen Pharma Ltd. ($URGN) on June 22, 2026. The trade was reported to the SEC in a Form 4 filing.
Since the trade, $URGN is up 3.1% after 1 week, up 20.2% after 1 month and down 1.2% to date (from the $34.99 close on Jun 22, 2026).
URGN
UroGen Pharma Ltd.
Key Points
- On June 22, 2026, Wildman Daniel George acquired 8,000 shares of URGN, highlighting ongoing insider interest.
- URGN shares traded near $35.80 on Wednesday, with the company's stock seeing active institutional involvement.
- Analysts like HC Wainwright & Co. and Oppenheimer maintain a 'buy' rating on URGN, with targets up to $45.
Get $URGN trade alerts by text
We text you when insiders, Congress or big funds trade $URGN. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated UroGen Pharma Ltd. alert may contain errors. Disclosures
Wildman Daniel George recently purchased 8,000 shares of URGN on June 22, 2026. This move is part of a broader trend of insider buying at the company. Shares of URGN were trading around $35.80 on Wednesday, reflecting a period of active insider and institutional interest.
Insider Buying and Selling at UroGen Pharma Ltd.
The recent activity at URGN saw several insiders buying shares. On June 22, 2026, James Robinson Jr. bought 18,000 shares, Leana Wen acquired 10,000 shares, Arie Belldegrun purchased 20,000 shares, and Cynthia Butitta added 10,000 shares to her holdings. These transactions were not made under a pre-planned trading scheme, suggesting a direct vote of confidence in the company's prospects.
Other Institutional Activity in URGN
Several institutional investors have also been active in URGN. BlackRock, Inc. increased its holdings by 244,558 shares, reaching 2,845,567 shares valued at about $51.16 million, marking a 9.4% increase. Toronto Dominion Bank opened a new position with 2,616,714 shares worth $47.05 million. Meanwhile, Morgan Stanley slightly reduced its position by 2,863 shares, holding 2,560,038 shares valued at approximately $46.03 million. Kynam Capital Management, LP also initiated a new stake, securing 2,247,393 shares worth about $40.41 million.
Analysts Set New Price Targets
Analysts remain bullish on URGN. On May 11, 2026, HC Wainwright & Co. maintained its 'buy' rating with a price target of $45. Similarly, Oppenheimer reaffirmed its 'buy' rating on May 7, 2026, with a target price of $40. These targets reflect analysts' confidence in the company's growth prospects.
Bottom Line
The recent insider buying activity at URGN, alongside institutional interest, suggests a strong belief in the company's future. While insider trades can offer insights into confidence levels, they are not a guarantee of future performance. Investors often pay attention to these moves as part of their broader analysis. As always, these filings are historical and may not reflect the current positions.
Related Filing Alerts
Source: Wildman Daniel George's Form 4 filing on $URGN (Jun 22, 2026). Find the original filing: URGN Form 4 filings on SEC EDGAR. Written by software, not financial advice. How we make alerts